Literature DB >> 24450684

Interreader agreement and variability of FDG PET volumetric parameters in human solid tumors.

Vasavi Paidpally1, Gustavo Mercier, Bhartesh A Shah, Srinivasan Senthamizhchelvan, Rathan M Subramaniam.   

Abstract

OBJECTIVE: The purpose of this article is to evaluate the interreader agreement and variability of two (18)F-FDG PET parameters, metabolic tumor volume and total lesion glycolysis, in human solid tumors.
MATERIALS AND METHODS: One hundred eleven patients (mean [± SD] age, 61.9 ± 12.5 years) with baseline staging FDG PET/CT scans were included. Two readers independently read the scans and segmented metabolic tumor volume and total lesion glycolysis using two fixed thresholds, 40% and 50% of the lesion's maximum standardized uptake value (SUVmax). The impact of the lesion's FDG avidity and location on reader agreement and variability was established. Intraclass correlation coefficient (ICC), precision, and Bland-Altman analysis were used to evaluate agreement and variability.
RESULTS: The ICCs for 40% and 50% SUVmax segmentations of metabolic tumor volume between the readers were 0.987 and 0.995, and the corresponding values for 40% and 50% SUVmax segmentations of total lesion glycolysis were 0.987 and 0.986, respectively (p = 0.0001). The corresponding precisions were 0.5%, 0.2%, 0.5%, and 0.5%, respectively. The mean biases between the readers for 40% and 50% SUVmax segmentations of metabolic tumor volume were -1.78 ± 8.42 mL and -0.46 ± 2.1 mL and for 40% and 50% SUVmax segmentations of total lesion glycolysis were -7.3 ± 31.6 g and -2.97 ± 12.86 g, respectively. Subgroup analysis showed better precision and lesser variability for 50% SUVmax segmentations of metabolic tumor volume and total lesion glycolysis in patients with the highest and lowest FDG-avid primary tumors. The precision was highest and variability was lowest for lung tumors.
CONCLUSION: There is excellent interreader agreement for measurement of metabolic tumor volume and total lesion glycolysis with 40% and 50% SUVmax threshold segmentations in human solid tumors.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24450684     DOI: 10.2214/AJR.13.10841

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  6 in total

1.  Quantitation of Cancer Treatment Response by 18F-FDG PET/CT: Multicenter Assessment of Measurement Variability.

Authors:  Joo Hyun O; Heather Jacene; Brandon Luber; Hao Wang; Minh-Huy Huynh; Jeffrey P Leal; Richard L Wahl
Journal:  J Nucl Med       Date:  2017-03-30       Impact factor: 10.057

2.  High FDG uptake areas on pre-radiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for locally advanced oesophageal cancer.

Authors:  Jérémie Calais; Bernard Dubray; Lamyaa Nkhali; Sebastien Thureau; Charles Lemarignier; Romain Modzelewski; Isabelle Gardin; Frederic Di Fiore; Pierre Michel; Pierre Vera
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-02-14       Impact factor: 9.236

3.  Practical no-gold-standard evaluation framework for quantitative imaging methods: application to lesion segmentation in positron emission tomography.

Authors:  Abhinav K Jha; Esther Mena; Brian Caffo; Saeed Ashrafinia; Arman Rahmim; Eric Frey; Rathan M Subramaniam
Journal:  J Med Imaging (Bellingham)       Date:  2017-03-03

4.  PET/CT imaging correlates with treatment outcome in patients with multidrug-resistant tuberculosis.

Authors:  Ray Y Chen; Lori E Dodd; Myungsun Lee; Praveen Paripati; Dima A Hammoud; James M Mountz; Doosoo Jeon; Nadeem Zia; Homeira Zahiri; M Teresa Coleman; Matthew W Carroll; Jong Doo Lee; Yeon Joo Jeong; Peter Herscovitch; Saher Lahouar; Michael Tartakovsky; Alexander Rosenthal; Sandeep Somaiyya; Soyoung Lee; Lisa C Goldfeder; Ying Cai; Laura E Via; Seung-Kyu Park; Sang-Nae Cho; Clifton E Barry
Journal:  Sci Transl Med       Date:  2014-12-03       Impact factor: 17.956

5.  Quantification of Metastatic Prostate Cancer Whole-Body Tumor Burden with 18F-FDG PET Parameters and Associations with Overall Survival After First-Line Abiraterone or Enzalutamide: A Single-Center Retrospective Cohort Study.

Authors:  Andreas G Wibmer; Michael J Morris; Mithat Gonen; Junting Zheng; Hedvig Hricak; Steven Larson; Howard I Scher; Hebert Alberto Vargas
Journal:  J Nucl Med       Date:  2021-01-08       Impact factor: 10.057

6.  The assessment of correlation and prognosis among 18F-FDG uptake parameters, Glut1, pStat1 and pStat3 in surgically resected non-small cell lung cancer patients.

Authors:  Hayato Kaida; Koichi Azuma; Akihiko Kawahara; Eiji Sadashima; Satoshi Hattori; Shinzo Takamori; Jun Akiba; Kiminori Fujimoto; Axel Rominger; Takamichi Murakami; Kazunari Ishii; Masatoshi Ishibashi
Journal:  Oncotarget       Date:  2018-08-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.